The collaboration plans to evaluate the combination of Marengo's first-in-class TCR Vβ selective dual T cell agonist, STAR0602 (Invikafusp alfa), with Trodelvy (sacituzumab govitecan-hziy) Gilead's Trop-2 directed ADC in a new multi-center Phase I/II clinical study (START-002).
The planned combination trial, sponsored by Marengo, is expected to commence soon. This study will evaluate the safety, tolerability, and preliminary efficacy of STAR0602 (Invikafusp alfa) in combination with Trodelvy in patients with metastatic TNBC or metastatic HR+/HER2- breast cancer, aiming to explore a novel therapeutic strategy that could offer new treatment options for patients.
Under the clinical study collaboration and supply agreement, Gilead will provide Trodelvy to Marengo, who will conduct and sponsor the combination study. Marengo and Gilead will retain all development and commercial rights to their respective compounds, including as monotherapy or as combination therapies.
The collaboration plans to evaluate the combination of Marengo's first-in-class TCR Vβ selective dual T cell agonist, STAR0602 (Invikafusp alfa), with Trodelvy (sacituzumab govitecan-hziy) Gilead's Trop-2 directed ADC in a new multi-center Phase I/II clinical study (START-002).
该合作计划在一项新的多中心I/II期临床研究（Start-002）中评估Marengo的同类首款TCR Vβ选择性双T细胞激动剂 STAR0602（Invikafusp alfa）与Trodelvy（sacituzumab govitecan-hziy）吉利德的Trop-2定向ADC的组合。
The planned combination trial, sponsored by Marengo, is expected to commence soon. This study will evaluate the safety, tolerability, and preliminary efficacy of STAR0602 (Invikafusp alfa) in combination with Trodelvy in patients with metastatic TNBC or metastatic HR+/HER2- breast cancer, aiming to explore a novel therapeutic strategy that could offer new treatment options for patients.
计划中的组合试验由Marengo赞助，预计将很快开始。该研究将评估 STAR0602（Invikafusp alfa）联合Trodelvy对转移性TNBC或转移性HR+/HER2-乳腺癌患者的安全性、耐受性和初步疗效，旨在探索一种新的治疗策略，为患者提供新的治疗选择。
Under the clinical study collaboration and supply agreement, Gilead will provide Trodelvy to Marengo, who will conduct and sponsor the combination study. Marengo and Gilead will retain all development and commercial rights to their respective compounds, including as monotherapy or as combination therapies.
根据临床研究合作和供应协议，吉利德将向Marengo提供Trodelvy，后者将进行和赞助联合研究。Marengo和吉利德将保留其各自化合物的所有开发和商业权利，包括单一疗法或联合疗法。
